Cover Image

Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer

Abstract Background Data are sparse concerning the sequential use of multiple anaplastic lymphoma kinase (ALK) inhibitors for ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Objective This study investigated sequencing and outcomes among patients receiving multiple AL...

Full description

Saved in:

Bibliographic Details
Main Authors:	David M. Waterhouse (Author), Janet L. Espirito (Author), Marc D. Chioda (Author), Bismark Baidoo (Author), Jack Mardekian (Author), Nicholas J. Robert (Author), Elizabeth T. Masters (Author)
Format:	Book
Published:	Adis, Springer Healthcare, 2020-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
by: Valerio Gristina, et al.
Published: (2020)

ALK positive histiocytosis in an adult female with an EML4-ALK RNA fusion
by: Jay Mehta, et al.
Published: (2020)

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
by: Jonathan R. Thompson, et al.
Published: (2016)

Tyrosine kinase inhibitors: new molecules in non-small cell lung cancer (EGFR AND ALK)
by: Fernando Franco, et al.
Published: (2017)

Therapeutic Sequencing in ALK<sup>+</sup> NSCLC
by: Mei Elsayed, et al.
Published: (2021)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
by: Hong Tao, et al.
Published: (2022)

Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report
by: Jiuzhou Zhao, et al.
Published: (2022)

mRNA Expression Level of ALK in Neuroblastoma Is Associated with Histological Subtype, ALK Mutations and ALK Immunohistochemical Protein Expression
by: Rixt S. Bruinsma, et al.
Published: (2024)

Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
by: Ali R, et al.
Published: (2019)

ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients
by: Uruga H, et al.
Published: (2018)

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
by: J. Guan, et al.
Published: (2016)

Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy
by: Chrisann Kyi, et al.
Published: (2021)

Identification and therapeutic evaluation of ALK rearrangements in non‐small‐cell lung cancer
by: Ruiying Zhao, et al.
Published: (2022)

ALK-positive histiocytosis of the umbilicus with KIF5B-ALK fusion: A case report and review of the literature
by: Yili Zhu, et al.
Published: (2021)

Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib
by: El-Osta H, et al.
Published: (2015)

Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study
by: A. S. Kolbin, et al.
Published: (2023)

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
by: Alfredo Addeo, et al.
Published: (2018)

Omental Metastasis from ALK-positive Lung Cancer - A Case Report
by: Taha Khalid, et al.
Published: (2020)

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
by: Pacenta HL, et al.
Published: (2018)

Core Biopsy Diagnosis of ALK Positive Inflammatory Myofibroblastic Tumor of Lung: An Interesting Case
by: Ritesh SACHDEV, et al.
Published: (2020)

Design, synthesis and biological evaluation of 2,4-pyrimidinediamine derivatives as ALK and HDACs dual inhibitors for the treatment of ALK addicted cancer
by: Dafeng Guo, et al.
Published: (2022)

Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer
by: Haoyue Hu, et al.
Published: (2023)

Diagnosis and Treatment of Advanced ALK Rearrangement-Positive Non-Small-Cell Lung Cancer in Portugal: Results of a National Questionnaire
by: Ana Figueiredo, et al.
Published: (2023)

Microfluidics-based immunofluorescence for fast staining of ALK in lung adenocarcinoma
by: Saška Brajkovic, et al.
Published: (2018)

Activin B can signal through both ALK4 and ALK7 in gonadotrope cells
by: Lee Katharine B, et al.
Published: (2006)

Interstitial lung disease associated with ALK inhibitors and risk factors: an updated comparative pharmacovigilance analysis
by: Junli Dong, et al.
Published: (2024)

ALK-Positive Histiocytosis: A Case Report and Literature Review
by: Omar Issa JABER, et al.
Published: (2021)

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
by: Daniele Marinelli, et al.
Published: (2022)

New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
by: Rothschild SI
Published: (2016)

Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer
by: Yan Hu, et al.
Published: (2022)

Prognostic role of ALK-1 and h-TERT expression in glioblastoma multiforme: correlation with ALK gene alterations
by: Dalia Elsers, et al.
Published: (2021)

ALK-positive large B-cell lymphomas: A clinicopathologic study
by: Jagan Chandramohan, et al.
Published: (2022)

Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells
by: Joelle C. Boulos, et al.
Published: (2021)

Autocrine EGF and TGF‐α promote primary and acquired resistance to ALK/c‐Met kinase inhibitors in non‐small‐cell lung cancer
by: Yueqin Wang, et al.
Published: (2023)

Synchronous BRCA2 positive ovarian carcinoma with ALK positive NSCLC: Double trouble
by: Ullas Batra, et al.
Published: (2022)

Case report: ALK D1225N missense mutation in lung adenocarcinoma responds to tyrosine kinase inhibitors
by: Jianxin Chen, et al.
Published: (2023)

Future Perspective for ALK-Positive Anaplastic Large Cell Lymphoma with Initial Central Nervous System (CNS) Involvement: Could Next-Generation ALK Inhibitors Replace Brain Radiotherapy for the Prevention of Further CNS Relapse?
by: Makito Tanaka, et al.
Published: (2023)

ALK, ROS1 and EGFR status of lung cancers in the Aegean Region of Turkey
by: Gulden Diniz, et al.
Published: (2022)

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer
by: Wenjie Liu, et al.
Published: (2024)

Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis
by: Kehai Lin, et al.
Published: (2022)